Traws Pharma (TRAW) Return on Capital Employed (2013 - 2026)
Traws Pharma (TRAW) posted quarterly Return on Capital Employed of 513.36% for Q1 2026, up 173943.0% year-over-year from N/an in Q1 2025, and up 111.03% quarter-over-quarter from 4654.95% in Q4 2025.
Traws Pharma (TRAW) Return on Capital Employed (2013 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Return on Capital Employed for 14 consecutive years, with 513.36% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 173943.0% year-over-year to 513.36%; the TTM figure through Mar 2026 stood at 513.36% (up 173943.0% YoY), while the FY2025 annual figure was 269.06%, up 88944.0% from the prior year.
- Return on Capital Employed improved to 513.36% in Q1 2026 per TRAW's latest filing, from 4654.95% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 513.36% in Q1 2026 and bottomed at 4654.95% in Q4 2025.
- Historically, Return on Capital Employed has averaged 790.15% across 5 years, with a median of 129.78% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 249899 bps — and 2025, when it jumped 233436 bps.
- Traws Pharma's Return on Capital Employed stood at 58.54% in 2022, then sank by 122 bps to 129.78% in 2023, then slumped by 1926 bps to 2628.77% in 2024, then slumped by 77 bps to 4654.95% in 2025, then soared by 111 bps to 513.36% in 2026.
- Business Quant data shows TRAW's Return on Capital Employed at 513.36% in Q1 2026, 4654.95% in Q4 2025, and 256.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | -27,620.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 513.36% |
| Dec 31, 2025 | -4,654.95% |
| Sep 30, 2025 | -256.85% |
| Jun 30, 2025 | -202.85% |
| Mar 31, 2025 | -1,226.07% |
| Dec 31, 2024 | -2,628.77% |
| Sep 30, 2024 | -2,591.21% |
| Jun 30, 2024 | -1,621.21% |
| Mar 31, 2024 | -176.03% |
| Dec 31, 2023 | -129.78% |
| Sep 30, 2023 | -113.06% |
| Jun 30, 2023 | -91.80% |
| Mar 31, 2023 | -77.28% |
| Dec 31, 2022 | -58.54% |
| Sep 30, 2022 | -45.75% |
| Jun 30, 2022 | -36.97% |
| Mar 31, 2022 | -34.80% |
| Dec 31, 2021 | -31.96% |
| Sep 30, 2021 | -42.05% |
| Jun 30, 2021 | -54.38% |